

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/588,414
		Filing Date	08/04/2006
		First Named Inventor	Kyle et al.
		Art Unit	
		Examiner Name	
Sheet 1	of 7	Attorney Docket Number	E1975-00043

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A	Ahne W, Bjorklund HV, Essbauer S, Fijan N, Kurath G, Winton JR (2002) Spring viremia of carp (SVC). Dis Aquat Organ 52:261-272;	
	B	Altmann F, Staudacher E, Wilson IB, Marz L (1999) Insect cells as hosts for the expression of recombinant glycoproteins. Glycoconj J 16:109-123	
	C	Anderson MM, Luring AS, Robertson S, Dirks C, Overbaugh J (2001) Feline Pit2 functions as a receptor for subgroup B feline leukemia viruses. J Virol 75:10563-10572	
	D	Bergeron J, Menezes J, Tijssen P (1993) Genomic organization and mapping of transcription and translation products of the NADL-2 strain of porcine parvovirus. Virology 197:86-	
	E	Bootland L, Lizama M, Lin W, Salenius K (2002) Oral immunization of salmonids with biodegradable microparticle-based vaccines. In: Harrington K (ed) 4th Intl. Symp. Aquatic An	
	F	Buxton F, Gwynne D, Davies R (1990) Aspergillus niger transformation system US Patent 4885249 assigned to Allelix Inc. Biotechnol. Adv. 8:388-389	
	G	Castillo A, Cifuentes V (1994) Presence of double-stranded RNA and virus-like particles in Phaffia rhodozyma. Curr. Genet. 26:364-368	
	H	Cereghino GP, Cregg JM (1999) Applications of yeast in biotechnology: protein production and genetic analysis. Curr. Opin. Biotechnol. 10:422-427	
	E	Cereghino JL, Cregg JM (2000) Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol. Rev. 24:45-66	
	J	Cha HJ, Dalal NG, Pham MQ, Vakharia VN, Rao G, Bentley WE (1999) Insect larval expression process is optimized by generating fusions with green fluorescent protein. Biotechnol. Bioeng. 65:316-324	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/588,414
Filing Date	08/04/2006
First Named Inventor	Kyle et al.
Art Unit	
Examiner Name	
Attorney Docket Number	E1975-00043

Sheet 2

of

7

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	K	Chang CF, Su MS, Chen HY, Liao IC (2003) Dietary beta-1,3-glucan effectively improves immunity and survival of <i>Penaeus monodon</i> challenged with white spot syndrome virus. <i>Fish Shellfish Immunol.</i> 15:297	
	L	Chen LL et al. (2002) Identification of a nucleocapsid protein (VP35) gene of shrimp white spot syndrome virus and characterization of the motif important for targeting VP35 to the nuclei of transfect	
	M	Cregg JM, Cereghino JL, Shi J, Higgins DR (2000) Recombinant protein expression in <i>Pichia pastoris</i> . <i>Mol. Biotechnol.</i> 16:23-52	
	N	Dhar AK, Dettori T, Roux MM, Klimpel K, Read B (2003) Identification of differentially expressed genes in white spot syndrome virus infected shrimp ( <i>Penaeus stylirostris</i> ) by cDNA microarrays. <i>Arch. Vi</i>	
	O	Dhar AK, Roux MM, Klimpel KR (2001) Detection and quantification of infectious hypodermal and hematopoietic necrosis virus and white spot virus in shrimp using real-time quantitative PCR and SYBR Green Chemistry. <i>J. Clin. Microbiol.</i> 39:2835-2845	
	P	el-Enshasy H, Hellmuth K, Rinas U (2001) GpdA-promoter-controlled production of glucose oxidase by recombinant <i>Aspergillus niger</i> using nonglucose carbon sources. <i>Appl. Biochem. Biotechnol.</i> 90:57-66	
	Q	Fischer R, Drossard J, Emans N, Commandeur U, Hellwig S (1999) Towards molecular farming in the future: <i>pichia pastoris</i> -based production of single-chain antibody fragments. <i>Biotechnol. Appl. Biochem.</i> 30 (pt 2): 117-120	
	R	Flegel T (1997) Major viral disease of black tiger prawn ( <i>Penaeus monodon</i> ) in Thailand. <i>World J Micro. Biotech.</i> 13:433-442	
	S	Fuller JD et al. (2002) Identification of a streptolysin S-associated gene cluster and its role in the pathogenesis of <i>Streptococcus iniae</i> disease. <i>Infect. Immun.</i> 70:5730-5739	
	T	Gibello A, Collins MD, Dominguez L, Fernandez-Garayzabal JF, Richardson PT (1999) Cloning and analysis of the L-lactate utilization genes from <i>Streptococcus iniae</i> . <i>Appl. Environ. Microbiol.</i> 65:4346-43	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/588,414
Filing Date	08/04/2006
First Named Inventor	Kyle et al.
Art Unit	
Examiner Name	
Attorney Docket Number	E1975-00043

Sheet 3

of

7

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	S	Hannon GJ (2002) RNA interference. Nature 418:244-251	
	U	Inouye K et al. (1994) Mass mortality of cultured kuruma shrimp <i>Penaeus japonicus</i> in Japan in 1993: Electron microscopic evidence of the causative virus. Fish Pathology 9:149-	
	V	Jarvis DL, Kavar ZS, Hollister JR (1998) Engineering N-glycosylation pathways in the baculovirus-insect cell system. Curr. Opin. Biotechnol. 9:528-533	
	W	Jory D, Dixon H (1999) Shrimp white spot virus in the Western Hemisphere. Aquacult. Mag. 25:83-91	
	X	Kamath RS, Martinez-Campos M, Zipperlen P, Fraser AG, Ahringer J (2002) Effectiveness of specific RNA-mediated interference through ingested double stranded RNA in <i>Caenorhabditis</i>	
	Y	Kamstrup S et al. (1998) Mapping the antigenic structure of porcine parvovirus at the level of peptides. Virus Res 53:163-173	
	Z	Kapusta J et al. (1999) A plant-derived edible vaccine against hepatitis B virus. FASEB J 13:1796-1799	
	AA	Kelemen Z et al. (2002) Transformation vector based on promoter and intron sequences of a replacement histone H3 gene. A tool for high, constitutive gene expression in plants. Transgenic Res. 11:69-72	
	BB	Khandelwal A, Vally K, Geetha N, Venkatachalam P, Shalla M, Sita G (2003) Engineering hemagglutinin (H) protein of rinderpest virus into peanut ( <i>Arachis hypogaea</i> L.) as a possible source of vaccine. Plant Sci. 165:77-84	
		Krishna R, Rao K, Rao PV, Babu P (1997) White spot disease. World Aquaculture 12:14-19	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/588,414
Filing Date	08/04/2006
First Named Inventor	Kyle et al.
Art Unit	
Examiner Name	
Attorney Docket Number	E1975-00043

Sheet 4

of

7

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CC	Krossoy B et al. (2001) Cloning and identification of the infectious salmon anaemia virus haemagglutinin. J Gen. Virol. 82:1757-1765	
	DD	Larrick JW, Yu L, Naftzger C, Jaiswal S, Wycoff K (2001) Production of secretory IgA antibodies in plants. Biomol. Eng. 18:87-94	
	EE	Liu L, Liu J, Qiu RX, Zhu XG, Dong ZY, Tang GM (2003) Improving heterologous gene expression in <i>Aspergillus niger</i> by introducing multiple copies of protein-binding sequence containing CCAAT to the promoter. Lett. Appl. Microb	
	FF	Marks H, Mennens M, Vlak JM, van Hulten MC (2003) Transcriptional analysis of the white spot syndrome virus major virion protein genes. J Gen. Virol. 84:1517-1523	
	GG	Martinez C, Hermosilla G, Leon R, Pincheira G, Cifuentes V (1998) Genetic transformation of astaxanthin mutants of <i>Phaffia rhodozyma</i> . Antonie Van Leeuwenhoek 73:147-153	
	HH	Mason HS, Lam DM, Arntzen CJ (1992) Expression of hepatitis B surface antigen in transgenic plants. Proc. Natl. Acad. Sci. U S A 89:11745-11749	
	II	Mayfield S, Franklin S, Lerner R (2003) Expression and assembly of a fully active antibody in algae. Proc. Nat. Acad. Sci. USA	
	JJ	Mayfield S, Kindle K (1990) Stable nuclear transformation of <i>Chlamydomonas reinhardtii</i> by using a <i>C. reinhardtii</i> gene as the selectable marker. Proc Natl Acad Sci U S A 87:2087-2091	
	KK	McCown M, Diamond MS, Pekosz A (2003) The utility of siRNA transcripts produced by RNA polymerase I in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses. Virology 313:514-524	
	LL	Namikoshia A et al. (2004) Vaccination trials with <i>Penaeus japonicus</i> to induce resistance to white spot syndrome virus. Aquacult. 229:25-35	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/588,414		
		Filing Date	08/04/2006		
		First Named Inventor	Kyle et al.		
		Art Unit			
		Examiner Name			
Sheet	5	of	7	Attorney Docket Number	E1975-00043

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	MM	Neely MN, Pfeifer JD, Caparon M (2002) Streptococcus-zebrafish model of bacterial pathogenesis. Infect. Immun. 70:3904-3914	
	NN	Raponi M, Arndt GM (2003) Double-stranded RNA-mediated gene silencing in fission yeast. Nucleic Acids Res. 31:4481-4489	
	OO	Reed AP, Jones EV, Miller TJ (1988) Nucleotide sequence and genome organization of canine parvovirus. J Virol. 62:266-276	
	PP	Saliki JT et al. (1992) Canine parvovirus empty capsids produced by expression in a baculovirus vector: use in analysis of viral properties and immunization of dogs. J Gen. Vi	
	QQ	Saravanan T, Reddy GR, Dechamma HJ, Suryanarayana VV (2003) Foot-and-mouth disease virus Asia 1 (FMDV-Asia1). In. Molecular Virology, Indian Veterinary Research Institute, Ind	
	RR	Schmaljohn CS, Chu YK, Schmaljohn AL, Dalrymple JM (1990) Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. J Virol. 64:3162-3170	
	SS	Shapira M, Arad SM, Lapidot M, Raveh D, Sivan A (2002) Stable chloroplast transformation of the unicellular red alga Porphyridium species. Plant Physiol. 129:7-12	
	TT	Shoemaker CA, Klesius PH, Evans JJ (2001) Prevalence of Streptococcus in tilapia, hybrid striped bass, and channel catfish on commercial fish farms in the United States. Am. J V	
	UU	Snow M, Ritchie R, Arnaud O, Villoing S, Aspehaug V, Cunningham CO (2003) Isolation and characterisation of segment 1 of the infectious salmon anaemia virus genome. Virus Res.	
	VV	Sultana K, Godward G, Reynolds N, Arumugaswamy R, Peiris P, Kailasapathy K (2000) Encapsulation of probiotic bacteria with alginate-starch and evaluation of survival in simula	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/588,414
Filing Date	08/04/2006
First Named Inventor	Kyle et al.
Art Unit	
Examiner Name	
Attorney Docket Number	E1975-00043

Sheet 6

of

7

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	WW	Ton G, Ni K, Cohen A, Mayfield S (2002) Construction of the anti-cocaine Fab genes for expression in the unicellular green alga Chlamydomonas reinhardtii. FASEB J 16:A542	
	XX	Toyomizu M, Suzuki K, Kawata Y, Kojima H, Akiba Y (2001) Effective transformation of the cyanobacterium Spirulina platensis using electroporation. J Appl. Phycol. 13:209-214	
	YY	Tsai MF et al. (2000a) Transcriptional analysis of the ribonucleotide reductase genes of shrimp white spot syndrome virus. Virology 277:92-99	
	ZZ	Tsai MF et al. (2000b) Identification and characterization of a shrimp white spot syndrome virus (WSSV) gene that encodes a novel chimeric polypeptide of cellular-type thymidine kinase and thymidylate kinase. Virology 277:100	
	AAA	van Hulten MC, Goldbach RW, Vlak JM (2000a) Three functionally diverged major structural proteins of white spot syndrome virus evolved by gene duplication. J Gen. Virol. 81:2525-2529	
	BBB	van Hulten MC, Westenberg M, Goodall SD, Vlak JM (2000b) Identification of two major virion protein genes of white spot syndrome virus of shrimp. Virology 266:227-236	
	CCC	van Hulten MC et al. (2001) The white spot syndrome virus DNA genome sequence. Virology 286:7-22	
	DDD	Vihinen-Ranta M, Wang D, Weichert WS, Parrish CR (2002) The VP1 N-terminal sequence of canine parvovirus affects nuclear transport of capsids and efficient cell infection. J Virol. 76:1884-1891	
	EEE	Walmsley AM, Arntzen CJ (2000) Plants for delivery of edible vaccines. Curr. Opin. Biotechnol. 11:126-129	
	FFF	Weinstein MR et al. (1997) Invasive infections due to a fish pathogen, Streptococcus iniae. S. iniae Study Group. N Engl. J Med. 337:589-594	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/588,414
Filing Date	08/04/2006
First Named Inventor	Kyle et al.
Art Unit	
Examiner Name	
Attorney Docket Number	E1975-00043

Sheet 7

of 7

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	GGG	Wery J, Gutker D, Renniers AC, Verdoes JC, van Ooyen AJ (1997) High copy number integration into the ribosomal DNA of the yeast <i>Phaffia rhodozyma</i> . <i>Gene</i> 184:89-9	
	HHH	Wiebe MG et al. (2001) Production of tissue plasminogen activator (t-PA) in <i>Aspergillus niger</i> . <i>Biotechnol Bioeng</i> 76:164-174	
	III	Wilson JA et al. (2003) RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. <i>Proc Natl. Acad. Sci. U S A</i> 100:2783-2788	
	JJJ	Xia H, Mao Q, Paulson HL, Davidson BL (2002) siRNA-mediated gene silencing in vitro and in vivo. <i>Nat. Biotechnol.</i> 20:1006-1010	
	KKK	Yang F et al. (2001) Complete genome sequence of the shrimp white spot bacilliform virus. <i>J Virol.</i> 75:11811-11820	
	LLL	Yi G, Qian J, Wang Z, Qi Y (2003) A phage-displayed peptide can inhibit infection by white spot syndrome virus of shrimp. <i>J Gen Virol.</i> 84:2545-2553	
	MMM	Zhang X, Xu X, Hew CL (2001) The structure and function of a gene encoding a basic peptide from prawn white spot syndrome virus. <i>Virus Res.</i> 79:137-144	
	NNN	Zlotkin A, Hershko H, Eldar A (1998) Possible transmission of <i>Streptococcus iniae</i> from wild fish to cultured marine fish. <i>Appl. Environ. Microbiol.</i> 64:4065-4067	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.